Figure 5
Topical administration of miR-155 inhibitor reduces inflammation and significantly improves wound healing kinetics in diabetic mice. (A) Wound size was assessed as percentage of initial size, along 10 days, in diabetic mice treated topically with 2.5 nmol of Neg. Ctrl. oligo and 1.00 and 2.50 nmol of miR-155 inhibitor (n = 6 for each group). (B) Representative images of Hematoxylin-Eosin staining and Herovici staining of mouse wound skin tissue of diabetic mice treated with Neg. Ctrl. Oligo (control) and 2.50 nmol of miR-155 inhibitor, collected at Day 10 post-wounding (n = 6 for each group with one representative example shown). Data were analyzed using Student’s t-test; *p < 0.05; **p < 0.01; ***p < 0.001 vs Neg. Ctrl. oligo.
